Last reviewed · How we verify
Q/LAIV (MEDI3250)
Q/LAIV is a live attenuated influenza vaccine (LAIV) engineered with a reassortant backbone to provide broad protection against seasonal influenza strains.
Q/LAIV is a live attenuated influenza vaccine (LAIV) engineered with a reassortant backbone to provide broad protection against seasonal influenza strains. Used for Seasonal influenza prevention in pediatric and adult populations.
At a glance
| Generic name | Q/LAIV (MEDI3250) |
|---|---|
| Also known as | MEDI3250 |
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine (LAIV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Q/LAIV uses a live but weakened influenza virus that replicates in the nasal mucosa to stimulate both mucosal and systemic immune responses. The vaccine is designed with a cold-adapted, temperature-sensitive master donor virus backbone combined with surface antigens from circulating seasonal influenza strains, allowing it to induce protective immunity while minimizing systemic reactogenicity.
Approved indications
- Seasonal influenza prevention in pediatric and adult populations
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
Key clinical trials
- A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age (PHASE2, PHASE3)
- A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Q/LAIV (MEDI3250) CI brief — competitive landscape report
- Q/LAIV (MEDI3250) updates RSS · CI watch RSS
- MedImmune LLC portfolio CI